Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| First Affiliated Hospital, Sun Yat-Sen University | OTHER |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | OTHER |
| Nanfang Hospital, Southern Medical University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention (PCI). The REICIN study has the potential to characterize contemporary CIN incidence, modified risk factors and prognosis, so that to identify strategiaes to reduce risk of CIN following CAG/PCI.
This is a multicenter prospective observational study collecting data on over 5000 CAG patients admitted to department of cardiology in 12 hospitals from January 2013. Data will be collected for more than 1 year on all patients undergoing CAG with or without PCI older than 18 years without baseline end-stage renal failure needing renal replacement therapy or renal transplantation. Data to be collected includes demographic information, admission diagnoses and co-morbidities, biomarkers and details on preventive hydration and medications used Contrast-induced nephropathy (CIN) is the primary endpoint, defined as a ≥ 0.5 mg/dL or 25% increase in serum creatinine (SCr) from baseline during the first 48 to 72 hours after the procedure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| coronary angiography | We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| contrast-induced nephropathy | Contrast-Induced Nephropathy was defined as a ≥ 0.5 mg/dL or 25% increase in serum creatinine from baseline during the first 48 to 72 hours after the procedure. | 48-72 h |
| Measure | Description | Time Frame |
|---|---|---|
| contrast-induced acute kidney injury (CI-AKI0.3) | defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure | 48h |
| Cystatin C based CI-AKI (CI-AKIcyc) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
We reviewed all consecutive patients who were undergoing coronary angiography
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yong Liu, MD,PhD | Guangdong Cardiovascular Institute,Guangdong General Hospital | Study Director |
| Shiqun Chen, MS | Guangdong Cardiovascular Institute,Guangdong General Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaihong Chen | Longyan | Fujian | China | |||
| Guoliang Jia |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| Guangzhou General Hospital of Guangzhou Military Command |
| OTHER |
| Guangdong Medical College | OTHER |
| Dongguan Kanghua Hospital | OTHER |
| Dongguan People's Hospital | OTHER_GOV |
| Maoming People's Hospital | OTHER |
| Futian People's Hospital | OTHER |
| Longyan City First Hospital | OTHER |
| First People's Hospital of Kashgar | UNKNOWN |
Not provided
Not provided
Not provided
defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.
| 24-48h |
| The change of eGFR, calculate based on CrCl and serum cystatin C | The eGFRcreatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 × min(Scr/κ, 1)α × max(Scr/κ, 1)-0.601 × min(Scys/0.8, 1)-0.375 × max (Scys/0.8, 1)-0.711 × 0.995Age [× 0.969 if female] [× 1.08 if black], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. | 48-72 h |
| Persistent CI-AKI (CI-AKIp) | defined as residual impairment of renal function indicated by a ≥ 25% reduction in creatinine clearance at 3 months in comparison with baseline. | 3 months |
| In-hospital major adverse cardiovascular and clinical events | all-cause mortality (cardiovascular and noncardiovascular), required renal replacement therapy (RRT), cardiovascular events (acute myocardial infarction, acute heart failure,cardiac shock, heart/ventricular septal rupture,clinical arrhythmia), Cerebrovascular events (Stroke), and bleeding (TIMI grade) . | In-hospital |
| Follow-up major adverse cardiovascular and clinical events | all-cause mortality, RRT, re-hospitalization, cardiovascular events, cerebrovascular events, and bleeding. | >=1 year |
| Dongguan |
| Guangdong |
| 510000 |
| China |
| Jianfeng Ye | Dongguan | Guangdong | 510000 | China |
| Jian Qiu | Guangzhou | Guangdong | 510000 | China |
| Jingfeng Wang | Guangzhou | Guangdong | 510000 | China |
| Ken Wu | Guangzhou | Guangdong | 510000 | China |
| Yuqing Hou | Guangzhou | Guangdong | 510000 | China |
| Zhiming Du | Guangzhou | Guangdong | 510000 | China |
| Guangdong General Hospital | Guangzhou | Guangdong | 510100 | China |
| Yan Liang | Maoming | Guangdong | 510000 | China |
| Guifu Wu | Shenzhen | Guangdong | China |
| Xiaoguang Zhou | Kashgar | Xinjiang | China |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |